NCT02898207 - Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

July 29, 2020

Study Completion Date

January 14, 2022

Conditions

Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous AdenocarcinomaMetastatic Triple-Negative Breast CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Breast CarcinomaRecurrent High Grade Fallopian Tube Serous AdenocarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous AdenocarcinomaRecurrent Triple-Negative Breast CarcinomaRefractory Fallopian Tube Serous AdenocarcinomaRefractory Ovarian Serous AdenocarcinomaRefractory Primary Peritoneal Serous AdenocarcinomaRefractory Triple-Negative Breast CarcinomaUnresectable High Grade Fallopian Tube Serous AdenocarcinomaUnresectable Malignant Solid NeoplasmUnresectable Primary Peritoneal Serous Adenocarcinoma

Interventions

DRUG

Olaparib

Given PO

DRUG

Onalespib

Given IV

Trial Locations (8)

55905

Mayo Clinic in Rochester, Rochester

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH